Jacobs Levy Equity Management’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Jacobs Levy Equity Management’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-8,881	Closed	-$106K	–	1108
2022 Q1	$106K	Sell	8,881 -1,450	-14%	-$25.9K	﹤0.01%	981
2021 Q4	$337K	Buy	10,331 +166	+2%	+$6.72K	﹤0.01%	886
2021 Q3	$454K	Buy	10,165 +5,909	+139%	+$288K	﹤0.01%	876
2021 Q2	$232K	Sell	4,256 -2,055	-33%	-$122K	﹤0.01%	968
2021 Q1	$472K	Sell	6,311 -5,949	-49%	-$618K	﹤0.01%	867
2020 Q4	$1.33M	Buy	12,260 +6,151	+101%	+$561K	0.01%	660
2020 Q3	$540K	Sell	6,109 -633	-9%	-$71.9K	0.01%	774
2020 Q2	$719K	Buy	6,742 +336	+5%	+$30.2K	0.01%	727
2020 Q1	$380K	Buy	6,406 +1,884	+42%	+$128K	﹤0.01%	792
2019 Q4	$312K	Buy	+4,522	New	+$274K	﹤0.01%	850
2019 Q2	–	Sell	-1,628	Closed	-$149K	–	1048
2019 Q1	$149K	Sell	1,628 -8,618	-84%	-$600K	﹤0.01%	921
2018 Q4	$571K	Buy	10,246 +2,360	+30%	+$179K	0.01%	712
2018 Q3	$939K	Buy	7,886 +220	+3%	+$25.5K	0.01%	660
2018 Q2	$783K	Buy	+7,666	New	+$949K	0.01%	716
2018 Q1	–	Sell	-1,717	Closed	-$167K	–	1074
2017 Q4	$167K	Buy	+1,717	New	+$231K	﹤0.01%	928

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

ABG

Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jacobs Levy Equity Management's SYRS Position: Q2 2022 in Review

Jacobs Levy Equity Management sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 8,881 shares — an estimated $106K sold.

Jacobs Levy Equity Management first reported a position in SYRS in Q4 2017 and held it in 15 quarters. The position peaked at $1.33M in Q4 2020. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

Jacobs Levy Equity Management reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
Jacobs Levy Equity Management sold 8,881 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $106K.
Jacobs Levy Equity Management first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 15 quarters.
Jacobs Levy Equity Management's Syros Pharmaceuticals, Inc. Common Stock position peaked at $1.33M in Q4 2020.
67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2022, filed 15 Aug 2022.